The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2020

Filed:

Aug. 02, 2018
Applicant:

Adaptive Biotechnologies Corp., Seattle, WA (US);

Inventors:

Thomas Asbury, San Francisco, CA (US);

Kieran Hervold, San Francisco, CA (US);

Chitra Kotwaliwale, Oakland, CA (US);

Malek Faham, Pacifica, CA (US);

Martin Moorhead, San Mateo, CA (US);

Li Weng, Fremont, CA (US);

Tobias Wittkop, San Mateo, CA (US);

Jianbiao Zheng, Fremont, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12P 19/34 (2006.01); C12Q 1/6874 (2018.01); G16B 20/00 (2019.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01); G16H 50/30 (2018.01); G06F 19/00 (2018.01); G16Z 99/00 (2019.01); C12Q 1/6881 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6874 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6886 (2013.01); G06F 19/00 (2013.01); G16B 20/00 (2019.02); G16H 50/30 (2018.01); G16Z 99/00 (2019.02); C12Q 1/6881 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/16 (2013.01); Y02A 90/26 (2018.01);
Abstract

The invention is directed to sequence-based profiling of populations of nucleic acids by multiplex amplification and attachment of one or more sequence tags to target nucleic acids and/or copies thereof followed by high-throughput sequencing of the amplification product. In some embodiments, the invention includes successive steps of primer extension, removal of unextended primers and addition of new primers either for amplification (for example by PCR) or for additional primer extensions. Some embodiments of the invention are directed to minimal residual disease (MRD) analysis of patients being treated for cancer. Sequence tags incorporated into sequence reads provide an efficient means for determining clonotypes and at the same time provide a convenient means for detecting carry-over contamination from other samples of the same patient or from samples of a different patient which were tested in the same laboratory.


Find Patent Forward Citations

Loading…